# US 2024/0199759 A1 · Bispecific antibodies targeting nkp46 and gpc3 and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199759 A1
- Document ID: US20240199759A1
- Status: Published application
- Kind: A1
- Application number: 18/285,628
- Filed: 2022-04-05
- Published: 2024-06-20
- Earliest claimed: 2021-04-05
- Assignees: Cytovia Therapeutics, LLC.
- Applicants: Cytovia Therapeutics, LLC.
- Inventors: Jean KADOUCHE; Wei LI; Daniel TEPER
- Web page: https://patentgrep.com/patent/US20240199759A1

## CPC

- C07K 16/303: {Liver or Pancreas}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/4261: {Proteoglycans, e.g. glypican, brevican or CSPG4}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/53: Liver
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2506/45: from artificially induced pluripotent stem cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure provides bispecific antibody molecules that specifically bind to NKp46 and Glypican 3 (GPC3). The disclosure further relates to combination therapies comprising the bispecific antibody molecules. The bispecific antibody molecules can be used to treat, prevent and/or diagnose cancer or infectious conditions or disorders associated with cells expressing NKp46 and/or GPC3.

## Claims

### Claim 1

A bispecific antibody that specifically binds NKp46 and Glypican 3 (GPC3), comprising:
i) a first heavy chain comprising
a heavy chain complementarity determining region 1 (CDRH1) comprising an amino acid sequence of SEQ ID NO: 17;
a heavy chain complementarity determining region 2 (CDRH2) comprising an amino acid sequence of SEQ ID NO: 18; and
a heavy chain complementarity determining region 3 (CDRH3) comprising an amino acid sequence of SEQ ID NO: 19;
ii) a first light chain comprising
a light chain complementarity determining region 1 (CDRL1) comprising an amino acid sequence of SEQ ID NO: 20;
a light chain complementarity determining region 2 (CDRL2) comprising an amino acid sequence of SEQ ID NO: 21; and
a light chain complementarity determining region 3 (CDRL3) comprising an amino acid sequence of SEQ ID NO: 22;
iii) a second heavy chain comprising
a CDRH1 comprising an amino acid sequence of SEQ ID NO: 32;
a CDRH2 comprising an amino acid sequence of SEQ ID NO: 33; and
a CDRH3 comprising an amino acid sequence of SEQ ID NO: 34; and
iv) a second light chain comprising
a CDRL1 comprising an amino acid sequence of SEQ ID NO: 35;
a CDRL2 comprising an amino acid sequence of SEQ ID NO: 36; and
a CDRL3 comprising an amino acid sequence of SEQ ID NO: 37; and
wherein the bispecific antibody comprises a first antigen binding region comprising i) and ii) that specifically binds to NKp46 and a second antigen binding region comprising iii) and iv) that specifically binds to GPC3.

### Claim 2 (depends on 1)

The bispecific antibody of claim 1, wherein
the first heavy chain comprises a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 23, 25, 27 or 29;
the first light chain comprises a first light chain variable region comprising an amino acid sequence of SEQ ID NO: 24, 26, 28 or 30;
the second heavy chain comprises a second heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 38; and
the second light chain comprises a second light chain variable region comprising an amino acid sequence of SEQ ID NO: 39.

### Claim 3 (depends on 1)

The bispecific antibody of claim 1, wherein the first antigen binding region comprises
a) a first heavy chain comprising a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 23 and a first light chain comprising a first light chain variable region comprising the amino acid sequence of SEQ ID NO: 24;
b) a first heavy chain comprising a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 25 and a first light chain comprising a first light chain variable region comprising the amino acid sequence of SEQ ID NO: 26;
c) a first heavy chain comprising a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 27 and a first light chain comprising a first light chain variable region comprising the amino acid sequence of SEQ ID NO: 28; or
d) a first heavy chain comprising a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 29 and a first light chain comprising a first light chain variable region comprising the amino acid sequence of SEQ ID NO: 30.

### Claim 4 (depends on 1)

The bispecific antibody of claim 1, wherein the second antigen binding region comprises:
a second heavy chain comprising a second heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 38 and a second light chain comprising a second light chain variable region comprising the amino acid sequence of SEQ ID NO: 39.

### Claim 5 (depends on 1)

The bispecific antibody of claim 1, wherein
a) the first heavy chain comprises a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 23; the first light chain comprises a first light chain variable region comprising an amino acid sequence of SEQ ID NO: 24; the second heavy chain comprises a second heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 38; and the second light chain comprises a second light chain variable region comprising an amino acid sequence of SEQ ID NO: 39;
b) the first heavy chain comprises a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 25; the first light chain comprises a first light chain variable region comprising an amino acid sequence of SEQ ID NO: 26; the second heavy chain comprises a second heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 38; and the second light chain comprises a second light chain variable region comprising an amino acid sequence of SEQ ID NO: 39;
c) the first heavy chain comprises a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 27; the first light chain comprises a first light chain variable region comprising an amino acid sequence of SEQ ID NO: 28; the second heavy chain comprises a second heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 38; and the second light chain comprises a second light chain variable region comprising an amino acid sequence of SEQ ID NO: 39; or
d) the first heavy chain comprises a first heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 29; the first light chain comprises a first light chain variable region comprising an amino acid sequence of SEQ ID NO: 30; the second heavy chain comprises a second heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 38; and the second light chain comprises a second light chain variable region comprising an amino acid sequence of SEQ ID NO: 39.

### Claim 6 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody comprises a fused heavy chain comprising an amino acid sequence of SEQ ID NO: 41, a first light chain comprising an amino acid sequence of SEQ ID NO: 31 and a second light chain comprising an amino acid sequence of SEQ ID NO: 40.

### Claim 7 (depends on 1)

The bispecific antibody of claim 1, wherein the bispecific antibody comprises an amino acid sequence of SEQ ID NO: 47, a first light chain comprising an amino acid sequence of SEQ ID NO: 31 and a second light chain comprising an amino acid sequence of SEQ ID NO: 40.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The bispecific antibody of any one of claims 1-7, wherein the bispecific antibody comprises at least two Fab fragments with different CH1 and CL domains, wherein said Fab fragments comprise:
a) a first Fab fragment consisting of:
i. the VH region and VL region that specifically binds NKp46;
ii. a CH1 domain of a human immunoglobulin comprising substitution of the threonine residue at position 192 of said CH1 domain with a glutamic acid residue; and
iii. a CL-kappa domain of a human immunoglobulin comprising substitution of the asparagine residue at position 137 of said CL domain with a lysine residue and substitution of the serine residue at position 114 of said CL domain with an alanine residue,
b) a second Fab fragment consisting of wild-type human CH1 and wild-type human CL domains of an immunoglobulin, and the VH region and VL region that specifically binds GPC3; and
wherein the sequence position numbers used for the CH1 and CL domains refer to Kabat numbering and Fab fragments are tandemly arranged in any order, and
wherein the C-terminal end of the CH1 domain of the first Fab fragment being linked to the N-terminal end of the VH domain of the following Fab fragment is through a polypeptide linker.

### Claim 9 (depends on 8)

The bispecific antibody of claim 8, wherein the polypeptide linker comprises an amino acid sequence of SEQ ID NO: 9 or 43.

### Claim 10 (depends on 8)

The bispecific antibody of claim 8, further comprising
c) a dimerized CH2 domain and CH3 domain of an immunoglobulin; and
d) a hinge region of an IgA, IgG, or IgD, linking the C-terminal ends of the CH1 domains of the antigen binding region to the N-terminal ends of the CH2 domains.

### Claim 11 (depends on 8)

The bispecific antibody of claim 8, further comprising an Fc domain derived from an IgG1 Fc domain or an IgG4 Fc domain.

### Claim 12 (depends on 11)

The bispecific antibody of claim 11, wherein the Fc domain region comprises an amino acid sequence of SEQ ID NO: 15.

### Claim 13 (depends on 11)

The bispecific antibody of claim 11, wherein the Fc domain region comprises an amino acid sequence of SEQ ID NO: 16.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The bispecific antibody of any one of claims 1-13, wherein the bispecific antibody is a human antibody, a humanized antibody or a chimeric antibody.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The bispecific antibody of any one of claims 1-14, wherein the IgG antibody is an IgG1 or an IgG4 antibody.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A nucleic acid sequence encoding any one of claims 1-15.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A multispecific antibody comprising the antigen binding regions of the bispecific antibody of any one of claims 1-15.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17)

A method of treating, preventing, or delaying the progression of pathologies associated with aberrant GPC3 expression or activity in a subject in need thereof, comprising administering an effective amount of the bispecific antibody of any one of claims 1-15 or the multispecific antibody of claim 17.

### Claim 19 (depends on 18)

The method of claim 18, wherein the pathology is cancer.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cancer is a solid tumor.

### Claim 21 (depends on 20)

The method of claim 20, wherein the solid tumor is hepatocellular carcinoma, lung carcinoma, head & neck cancer, ovarian cancer, breast cancer, esophageal carcinoma.

### Claim 22 (depends on 21)

The method of claim 21, wherein the solid tumor is hepatocellular carcinoma.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17)

A method of redirecting a NK cell response in a subject in need thereof, comprising administering an effective amount of the bispecific antibody of any one of claims 1-15 or the multispecific antibody of claim 17.

### Claim 24 (depends on 23)

The method of claim 23, wherein the NK cell response is NK-mediated cytotoxicity or antibody-dependent cellular cytotoxicity (ADCC).

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of promoting specific lysis of cells expressing Glypican 3 (GPC3+ cells) by natural killer (NK) cells, comprising contacting the GPC3+cells with an effective amount of the bispecific antibody according to any one of claims 1-15,
wherein the effective amount is an amount sufficient to promote the specific lysis of the GPC3+ cells by NK cells.

### Claim 26 (depends on 25)

The method of claim 25, wherein the GPC3+ cells are hepatocellular carcinoma cells.

### Claim 27 (depends on 25)

The method of claim 25, wherein the contacting step comprises administering the bispecific antibody to a subject suffering from or a risk for hepatocellular carcinoma.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A method of inhibiting proliferation of hepatocellular carcinoma cells or GPC3+ cancer cells in a subject treated with a bispecific antibody according to any one of claims 1-15, comprising administering an effective amount of natural killer (NK) cell.

### Claim 29 (depends on 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 18-24, wherein the method comprises administering an effective amount of natural killer (NK) cells.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A combination therapy or a kit for treatment of hepatocellular carcinoma or a GPC3+ cancer, comprising NK cells and a bispecific antibody according to any one of claims 1-15.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The bispecific antibody according to any one of claims 1-15 for use in combination with NK cells.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

Use of natural killer (NK) cells and a bispecific antibody according to any one of claims 1-15 for treatment of hepatocellular carcinoma or a GPC3+ cancer.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A kit comprising a bispecific antibody of any one of claims 1-15.

### Claim 34 (depends on 25, 26, 27, 28, 29)

The method of any one of claims 25-29, wherein the NK cells are induced pluripotent stem cell-derived natural killer (iPSC-NK) cells.

### Claim 35 (depends on 25, 26, 27, 28, 29)

The method of any one of claims 25-29, wherein the NK cells are donor-derived NK cells.

### Claim 36 (depends on 25, 26, 27, 28, 29)

The method of any one of claims 25-29, wherein, the NK cells are irradiated immortalized NK cells.

### Claim 37 (depends on 25, 26, 27, 28, 29)

The method of any one of claims 25-29, wherein the GPC3+ cancer is a solid tumor.
